1 / 11

IOM recommendations on drug safety: relevance for vaccines?

IOM recommendations on drug safety: relevance for vaccines?. Bruce M Psaty, MD, PhD. Drugs and vaccines: prevention. Drugs Vaccines. Payment Ad hoc VFC program. Injury comp Tort law No-fault system. Rx duration Long Short. Rapid uptake DTCA Guidelines.

donagh
Download Presentation

IOM recommendations on drug safety: relevance for vaccines?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. IOM recommendations on drug safety: relevance for vaccines? Bruce M Psaty, MD, PhD

  2. Drugs and vaccines: prevention Drugs Vaccines Payment Ad hoc VFC program Injury comp Tort law No-fault system Rx duration Long Short Rapid uptake DTCA Guidelines Phase III standard Surrogates Clinical benefit PM safety events Uncommon Rare Orenstein WA. Health Affairs 2005; 24: 599-610.

  3. US drug-safety system • Pharmaceutical industry lacks a symmetric interest in safety and efficacy • Since 1960s, approval marks transition from evaluation to marketing • With rapid approvals since 1992, current post-market system--AERS plus PM commitments--could hardly be weaker Steenburg C. Food Drug Law 2006; 61: 295-384.

  4. Guidance to assess safety • For new drugs intended for long-term use in non-life threatening conditions • 1500 subjects exposed • 300 to 600 subjects for 6 months • 100 subjects for 1 year • Rofecoxib NDA as example • 58 studies in 5771 patients • 3629 received rofecoxib 1 day or more • 752 received usual doses for 1 year Guidance ICH E1a, 1995. Villalba M. Review of Vioxx, 1999.

  5. US post-market safety system • FDA-based part of the system • AERS and some observational studies • Industry-based part of the system • PM commitments and other studies • 66% of med officers lack confidence that the “FDA adequately monitors the safety of prescription drugs … on the market” OIG Report. OEI-01-01-00590. March 2003.

  6. Post-market commitments • Agreed to by sponsors pre-approval • For one sponsor, 7 of 11 PMCs identified within 3 weeks of approval • Designed by sponsors, who often lack an imaginative interest in safety studies • Reviewed by OND medical officers, who often don’t know what studies to request OIG report. FDA review process, March 2003.

  7. Industry-funded studies • MEDAL program with 24,913 subjects • Compared etoricoxib and diclofenac • Similar pain relief, GI and CV AEs • Diclofenac as comparator • Best selling NSAID world-wide • COX2 selectivity similar to celecoxib • Compared with naproxen, 70% increase in vascular events Psaty BM. N Engl J Med 2007; 356: 328-30.

  8. Lifecycle approach • On-going evaluation of safety and efficacy of drugs during their market life • Systematic approach to identifying and translating safety signals into high-quality studies • Pursuit and management of emerging knowledge about risks and benefits

  9. IOM recommendations • New funding, preferably from general revenues rather than user fees • New authorities for the FDA • Labeling and post-market studies • New enforcement tools • Black triangle and restricted direct to consumer advertising

  10. IOM recommendations • Leadership promoting a culture of safety • Access to new tools and new data • Integration of ODS/OSE in OND reviews and shared for post-market decisions • Development and use of risk-benefit analyses

  11. Some potential remedies • Congressional legislation • Clinical trials registration (S467) • Grassley-Dodd bill (S468) • Kennedy-Enzi bill (S484) • PUDFA reauthorization in 2007 • Wise drug use by physicians & patients • Suspend use of some drugs • Use well-studied drugs

More Related